Table 5. 1-, 3-, and 5-year overall and tumor-free survival rate comparison.
| 1-, 3-, and 5-year overall survival rate (%) |
P value | 1-, 3-, and 5-year tumor-free survival rate (%) |
P value | |||||
|---|---|---|---|---|---|---|---|---|
| 1-year | 3-year | 5-year | 1-year | 3-year | 5-year | |||
| Solitary radical therapy group (n = 1133) | 92.0% | 80.5% | 66.2% | 0.955 | 88.3% | 65.1% | 56.3% | 0.746 |
| TACE combined group (n = 427) | 92.3% | 78.5% | 66.7% | 84.3% | 66.3% | 54.8% | ||
| Solitary RFA group (163) | 91.4% | 79.1% | 60.7% | 0.958 | 82.8% | 62.6% | 47.2% | 0.696 |
| TACE combined with RFA group (81) | 91.4% | 77.8% | 61.7% | 80.2% | 61.7% | 44.4% | ||
| Solitary resection group (633) | 92.3% | 81.5% | 66.5% | 0.861 | 82.6% | 63.0% | 55.6% | 0.678 |
| TACE combined with resection group (268) | 92.5% | 78.7% | 67.5% | 84.7% | 66.4% | 56.3% | ||
| Solitary LT group (337) | 91.7% | 79.2% | 68.5% | 0.939 | 85.2% | 70.3% | 62.0% | 0.782 |
| TACE combined with LT group (78) | 92.3% | 78.2% | 69.2% | 87.2% | 70.5% | 60.3% | ||
TACE: transarterial chemoembolization; RFA: Radiofrequency ablation; LT: liver transplantation.